3Molor-Erdene P, Okajima K, Isobe H,et al. Inhibition of lipopolysac-charide-induced tissue factor expression in monocytes by urinau trypsininhibitor in vitro and invivo[ J ]. Thromb Haemost, 2005,94 ( 1 ) :136-145.
4Ito K, Mizutani A, Shinitiro K, et al. Effect of ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute hmg injury in rats via the inhibition of activated leukocytes[ J ]. Injury, 2005,36 (3) :387-394.
5Inoue K, Takano H, Toshikazu Yoshikawa. Protective role of urinary trypsin inhibitor in acute lung injury induced by lysaccharide. Exp Biol Med ,2005,230(4) :281-287.
3Bone RC.Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome(SIRS) and the multiple organ dysfunction syndrome(MODS)[].Annals of Internal Medicine.1996
4Nathens AB,Marshall JC.Sepsis, SIRS and MODS: what is in a name[].World Journal of Surgery.1996
5Ruetten H,Thiemermann C.Combination immunotherapy which neutralises the effect of TNF alpha and IL-1 beta attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat[].Journal of Physiology and Pharmacology.1997
6Walter L,Emest E,Frederick A,et al.Interleukin-6 in the injured patient[].Annals of Surgery.1996
7Terregino C A,Quinn J V,Slotman G J.Pilot study of cytokines in emergency department patients with systemic inflammatory response syndrome[].Academic Emergency Medicine.1997
8Knaus WA,Draper FA,Wagner DP,et al.APACHE II: a severity of disease classification system[].Critical Care Medicine.1985
9Bone RC,Balk RA,Cerra FB,et al.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[].Critical Care Medicine.1992
10Amy M,Anthony J,Howard A,et al.Cytokines and actue pancreatitis[].Gastroenterology.1996
